Apixaban
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Apixaban |
| DrugBank ID | DB06605 |
| Brand Names (EU) | Eliquis |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.02% |
Approved Indication (EMA)
Treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age. AdultsPrevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension;
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | migraine disorder | 99.02% | DL |
| 2 | migraine with or without aura, susceptibility to | 98.92% | DL |
| 3 | leprosy | 98.90% | DL |
| 4 | rheumatoid arthritis | 98.89% | DL |
| 5 | migraine with brainstem aura | 98.83% | DL |
| 6 | Prinzmetal angina | 98.39% | DL |
| 7 | brachydactyly-syndactyly syndrome | 98.18% | DL |
| 8 | pulmonary hypertension | 98.13% | DL |
| 9 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | 98.00% | DL |
| 10 | kyphoscoliotic heart disease | 97.87% | DL |
| 11 | atrophoderma vermiculata | 97.86% | DL |
| 12 | ulerythema ophryogenesis | 97.52% | DL |
| 13 | thrombotic disease | 97.03% | DL |
| 14 | hemoglobinopathy | 96.52% | DL |
| 15 | female breast carcinoma | 96.49% | DL |
| 16 | nephrogenic syndrome of inappropriate antidiuresis | 96.32% | DL |
| 17 | gout | 96.31% | DL |
| 18 | lymphocytic hypereosinophilic syndrome | 96.30% | DL |
| 19 | collagenopathy | 96.26% | DL |
| 20 | conjunctivitis | 96.14% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.